![]() Cue Biopharma Cue Biopharma is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. | ![]() Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| ![]() Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. | ![]() Momenta Pharmaceuticals Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. | ![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2015 | Founding Date 2006 | Founding Date 2002 | Founding Date 2001 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations San Diego, US HQ San Diego, US | Locations Coral Gables, US HQ | Locations Cambridge, US HQ Dublin, IE Cambridge, US | |
Employees | Employees 4664% increase | Employees 31019% decrease | Employees 7649% increase | Employees 761% decrease | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 107.3 m | Valuation ($) 1.5 m | Valuation ($) 2.6 b | Valuation ($) N/A | Valuation ($) 36.5 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $9.3m (FY, 2024) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $491.7m (FY, 2024) | Revenue (est.) $23.9m (FY, 2019) | Revenue (est.) $2.2b (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $68.8m (FY, 2024) | Cost of goods N/A | Cost of goods $306.5m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $422.9m (FY, 2024) | Gross profit N/A | Gross profit $1.9b (FY, 2024) |
Net income | Net income ($40.7m) (FY, 2024) | Net income ($577.8m) (FY, 2022) | Net income $163.9m (FY, 2024) | Net income ($290.1m) (FY, 2019) | Net income ($278.2m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 1.5b |
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyCatalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View companyMomenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.
View companyAlnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company